Study Evaluating Venetoclax in Subjects With Hematological Malignancies
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)Small Lymphocytic Lymphoma (SLL)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 38
- Registration Number
- NCT02265731
- Locations
- 🇯🇵
Nagoya City University Hospital /ID# 129278, Nagoya shi, Aichi, Japan
🇯🇵NHO Nagoya Medical Center /ID# 129222, Nagoya-shi, Aichi, Japan
🇯🇵Aichi Cancer Center Hospital /ID# 129061, Nagoya-shi, Aichi, Japan
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
- Conditions
- Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myeloid SarcomaChronic Myelogenous Leukemia (CML)Juvenile Myelomonocytic Leukemia (JMML)Myelodysplastic Syndrome (MDS)Non-Hodgkin Lymphoma (NHL)
- Interventions
- Biological: G-CSFBiological: Interleukin-2Biological: Natural killer cell therapyBiological: T-cell depleted HPC transplantBiological: CD45RA-depleted HPC transplant
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02259348
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myelocytic LeukemiaAcute Non-Lymphocytic LeukemiaAcute Myelogenous LeukemiaAcute Granulocytic Leukemia
- Interventions
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02255162
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT02252107
- Locations
- 🇧🇪
University of Liège, Liège, Belgium
🇳🇱University Medical Center Groningen (UMCG), Groningen, Netherlands
🇳🇱Radboud university medical center, Nijmegen, Netherlands
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (Relapsed/Refractory)
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- GSO Global Clinical Research BV
- Target Recruit Count
- 42
- Registration Number
- NCT02249091
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
- Conditions
- Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT02238925
- Locations
- 🇺🇸
Franciscan Saint Francis Health, Indianapolis, Indiana, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
- Conditions
- Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Myelodysplastic Syndrome (MDS)Mixed Phenotype Acute Leukemia (MPAL)
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02212561
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
- Conditions
- Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT02204020
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Conditions
- High-risk Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2014-07-23
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 6
- Registration Number
- NCT02198482
- Locations
- 🇩🇪
Hospital Aschaffenburg, Aschaffenburg, Germany
🇩🇪Helios Hospital Bad Saarow, Bad Saarow, Germany
🇩🇪Vivantes Hospital Am Urban, Berlin, Germany
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02196857
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States